Manchester, United Kingdom
F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developing therapies for life-threatening invasive fungal infections. Central to F2G's innovation is the creation of a novel class of antifungal agents called orotomides, which uniquely target fungal dihydroorotate dehydrogenase (DHODH).
The company's lead candidate, Olorofim, demonstrates fungicidal efficacy against numerous mould infections, including resistant and rare strains. Having completed a Phase 3 trial, Olorofim distinguishes itself within the industry, earning orphan drug status from the European Medicines Agency and multiple designations from the FDA.
Recently, F2G secured a $70.00M Private Equity Round on 04 August 2022, attracting investments from Sofinnova Partners and Forbion. This injection will support ongoing research and potential market expansion, positioning F2G as a significant entity within the Biotechnology, Health Care, and Pharmaceutical industries.
